TY - JOUR
T1 - Long-term outcomes of per-oral endoscopic myotomy in patients with achalasia with a minimum follow-up of 2 years
T2 - an international multicenter study
AU - Ngamruengphong, Saowanee
AU - Inoue, Haruhiro
AU - Chiu, Philip Wai Yan
AU - Yip, Hon Chi
AU - Bapaye, Amol
AU - Ujiki, Michael
AU - Patel, Lava
AU - Desai, Pankaj N.
AU - Hayee, Bu
AU - Haji, Amyn
AU - Wong, Vivien Wai yin
AU - Perretta, Silvana
AU - Dorwat, Shivangi
AU - Pioche, Mathieu
AU - Roman, Sabine
AU - Rivory, Jérôme
AU - Mion, François
AU - Ponchon, Thierry
AU - Garros, Aurélien
AU - Nakamura, Jun
AU - Hata, Yoshitaka
AU - Balassone, Valerio
AU - Onimaru, Manabu
AU - Hajiyeva, Gulara
AU - Ismail, Amr
AU - Chen, Yen I.
AU - Bukhari, Majidah
AU - Haito-Chavez, Yamile
AU - Kumbhari, Vivek
AU - Maselli, Roberta
AU - Repici, Alessandro
AU - Khashab, Mouen A.
N1 - Publisher Copyright:
© 2017 American Society for Gastrointestinal Endoscopy
PY - 2017/5
Y1 - 2017/5
N2 - Background and Aims Per-oral endoscopic myotomy (POEM) has shown promising safety and efficacy in short-term studies. However, long-term follow-up data are very limited. The aims of this study were to assess (1) clinical outcome of patients with a minimum post-POEM follow-up of 2 years and (2) factors associated with long-term clinical failure after POEM. Methods A retrospective chart review was performed that included all consecutive patients with achalasia who underwent POEM with a minimum follow-up of 2 years at 10 tertiary-care centers. Clinical response was defined by a decrease in Eckardt score to 3 or lower. Results A total of 205 patients (45.8% men; mean age, 49 years) were followed for a median of 31 months (interquartile range, 26-38 months). Of these, 81 patients (39.5%) had received previous treatment for achalasia before POEM. Clinical success was achieved in 98% (185/189), 98% (142/144), and 91% (187/205) of patients with follow-up within 6 months, at 12 months, and ≥24 months, respectively. Of 185 patients with clinical response at 6 months, 11 (6%) experienced recurrent symptoms at 2 years. History of previous pneumatic dilation was associated with long-term treatment failure (odds ratio, 3.41; 95% confidence interval, 1.25-9.23). Procedure-related adverse events occurred in 8.2% of patients and only 1 patient required surgical intervention. Abnormal esophageal acid exposure and reflux esophagitis were documented in 37.5% and 18% of patients, respectively. However, these rates are simply a reference number among a very selective group of patients. Conclusions POEM is safe and provides high initial clinical success and excellent long-term outcomes. Among patients with confirmed clinical response within 6 months, 6% had recurrent symptoms by 2 years.
AB - Background and Aims Per-oral endoscopic myotomy (POEM) has shown promising safety and efficacy in short-term studies. However, long-term follow-up data are very limited. The aims of this study were to assess (1) clinical outcome of patients with a minimum post-POEM follow-up of 2 years and (2) factors associated with long-term clinical failure after POEM. Methods A retrospective chart review was performed that included all consecutive patients with achalasia who underwent POEM with a minimum follow-up of 2 years at 10 tertiary-care centers. Clinical response was defined by a decrease in Eckardt score to 3 or lower. Results A total of 205 patients (45.8% men; mean age, 49 years) were followed for a median of 31 months (interquartile range, 26-38 months). Of these, 81 patients (39.5%) had received previous treatment for achalasia before POEM. Clinical success was achieved in 98% (185/189), 98% (142/144), and 91% (187/205) of patients with follow-up within 6 months, at 12 months, and ≥24 months, respectively. Of 185 patients with clinical response at 6 months, 11 (6%) experienced recurrent symptoms at 2 years. History of previous pneumatic dilation was associated with long-term treatment failure (odds ratio, 3.41; 95% confidence interval, 1.25-9.23). Procedure-related adverse events occurred in 8.2% of patients and only 1 patient required surgical intervention. Abnormal esophageal acid exposure and reflux esophagitis were documented in 37.5% and 18% of patients, respectively. However, these rates are simply a reference number among a very selective group of patients. Conclusions POEM is safe and provides high initial clinical success and excellent long-term outcomes. Among patients with confirmed clinical response within 6 months, 6% had recurrent symptoms by 2 years.
UR - http://www.scopus.com/inward/record.url?scp=85007504218&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007504218&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2016.09.017
DO - 10.1016/j.gie.2016.09.017
M3 - Article
C2 - 27663714
AN - SCOPUS:85007504218
SN - 0016-5107
VL - 85
SP - 927-933.e2
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 5
ER -